ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022 DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.

May 09, 2025

Vol.51 No.18

Clinical

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

May 02, 2025

Vol.51 No.17

By Jacquelyn Cobb

Advancing quality of life in oncology: A journey of compassion and innovation

The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion.

David Ryan named president of Mass General Brigham Cancer Institute

David Ryan was named the inaugural president of the Mass General Brigham’s Cancer Institute following a national search process.

May 02, 2025

Vol.51 No.17

In Brief

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

Diane Reidy-Lagunes joined Duke University School of Medicine’s Department of Medicine as chief of the Division of Medical Oncology, effective April 1.

May 02, 2025

Vol.51 No.17

Cancer Policy

ASCO seeks to engage new leaders of NIH, CMS, and FDA

The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

YOU MAY BE INTERESTED IN

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Advancing quality of life in oncology: A journey of compassion and innovation

David Ryan named president of Mass General Brigham Cancer Institute

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Renew today!

Subscriber content

Never miss an issue!

Login